CMCh Hyperosmolar Eye Drops for Corneal Edema and Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hyperosmolar eye drops used to treat corneal edema cause osmotic shock to corneal cells and lack effective antimicrobial activity, particularly increasing the risk of bacterial infections like endophthalmitis after ocular surgery.
Innovation Solution
A hyperosmolar ophthalmic composition containing carboxymethyl chitosan (CMCh) with specific molecular and deacetylation characteristics, combined with osmolarity agents and viscosity regulators, to provide synergistic bacterial suppression and osmotic balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hyperosmolar eye drops containing high concentration of sodium chloride are used to treat corneal edema, then corneal swelling is reduced, but osmotic shock damages corneal cells and antimicrobial activity is insufficient
Solution Approach 1:
The patent changes the chemical composition parameters of the hyperosmolar solution by incorporating carboxymethyl chitosan (CMCh) at concentrations of 0.1-2.0% w/v alongside sodium chloride (3-6% w/v). This parameter modification allows the solution to maintain high osmolarity (1000-2000 mOsm/L) for edema treatment while CMCh provides protective and antimicrobial effects that mitigate osmotic shock damage to corneal cells.
Solution Approach 2:
The patent creates a composite ophthalmic composition combining multiple substances: carboxymethyl chitosan (CMCh), sodium chloride, buffer systems (phosphate, citrate, or borate), and optionally preservatives. This composite formulation synergistically provides hyperosmolar dehydration effect for edema reduction while CMCh contributes mucoprotective, healing, and broad-spectrum antimicrobial properties to protect corneal cells from osmotic damage.
2Quantity of substance
If hyperosmolar eye drops are used to treat corneal edema, then fluid accumulation is reduced, but bacterial infection risk increases due to lack of antimicrobial activity
Solution Approach 1:
The patent makes the hyperosmolar solution multi-functional by incorporating carboxymethyl chitosan (CMCh) which simultaneously provides: (1) antimicrobial protection against bacteria, fungi, and viruses; (2) mucoprotective and healing effects on corneal epithelium; and (3) enhancement of the overall therapeutic effect. This allows a single composition to address edema reduction, infection prevention, and tissue protection without requiring separate medications.
Solution Approach 2:
The composite formulation combines CMCh with sodium chloride and buffer systems to create a synergistic preparation where CMCh provides broad-spectrum antimicrobial activity (including against Pseudomonas aeruginosa, Staphylococcus aureus, and fungal pathogens) while the hyperosmolar sodium chloride component continues to provide effective edema reduction.
3Reliability
If carboxymethyl chitosan is added to provide antimicrobial activity, then bacterial growth is suppressed, but solution stability and solubility must be maintained
Solution Approach 1:
The patent optimizes the concentration parameters of carboxymethyl chitosan (0.1-2.0% w/v) and sodium chloride (3-6% w/v) to achieve the desired antimicrobial activity while maintaining solution stability. The buffer system (phosphate, citrate, or borate at pH 6.5-7.5) is also carefully parameterized to ensure CMCh remains soluble and stable in the hyperosmolar environment, preventing precipitation or degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces corneal edema while simultaneously preventing bacterial growth and infection, including endophthalmitis, by leveraging CMCh's strong antimicrobial properties in high osmolar solutions.
Implementation Method 1
hyperosmolar ophthalmic composition comprising carboxymethyl chitosan... suitable for the treatment of, inter alia, corneal edema
Implementation Method 2
preventing or decreasing the risk for bacterial infection and/or bacterial growth on the cornea
Data Source
Figure 1~2
AI summary
The invention provides a hyperosmolar ophthalmic composition comprising carboxymethyl chitosan. The ophthalmic composition can be used for treating corneal edema and for suppressing bacterial growth on the eye.